Proto-Oncogene Proteins c-met

• 

  Subject Areas on Research

  • A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. 
  • A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. 
  • Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis. 
  • Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility. 
  • Activating mutation in MET oncogene in familial colorectal cancer. 
  • Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway. 
  • Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence. 
  • An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. 
  • Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. 
  • Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts. 
  • Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. 
  • Decreased fibronectin expression in Met/HGF-mediated tumorigenesis. 
  • Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. 
  • Development of a Novel c-MET-Based CTC Detection Platform. 
  • Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. 
  • EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. 
  • Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. 
  • Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. 
  • First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. 
  • Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors. 
  • Hepatocyte growth factor and myopia: genetic association analyses in a Caucasian population. 
  • Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5. 
  • Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. 
  • Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. 
  • Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors. 
  • MET and phosphorylated MET as potential biomarkers in lung cancer. 
  • Met and hepatocyte growth factor/scatter factor expression in human gliomas. 
  • Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia. 
  • Novel role for endogenous hepatocyte growth factor in the pathogenesis of intracranial aneurysms. 
  • PTEN reconstitution alters glioma responses to c-Met pathway inhibition. 
  • Pathogenic Germline Variants in 10,389 Adult Cancers. 
  • Personalized treatment of lung cancer. 
  • Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. 
  • Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. 
  • Profiling the dynamics of a human phosphorylome reveals new components in HGF/c-Met signaling. 
  • Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. 
  • Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma. 
  • Targeting MET Amplification with Crizotinib in a Case of Sinonasal Undifferentiated Carcinoma. 
  • The role of cytoprotective cytokines in cardiac ischemia/reperfusion injury. 
  • Three-genome mosses: complex double allopolyploid origins for triploid gametophytes in Sphagnum. 
  • c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival. 
• 

  Keywords of People

  • Taylor, Gregory Alan, Professor in Medicine, Immunology